---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-008129"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:09:15.412635+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics Q1 net loss $0.22/shr; cash $12.7M; GT-02287 Phase 1 SAD positive

## Summary
- GAAP net loss per share $0.22 (Q1 2024) vs $0.43 (Q1 2023); narrower loss.
- Cash, equivalents & marketable securities $12.7M as of March 31, 2024; cash runway guided into 2025.
- R&D expenses $2.5M (down from $2.8M YoY); G&A expenses $1.9M (down from $2.5M YoY).
- Positive SAD data for GT-02287; MAD part of Phase 1 initiated for GBA1 Parkinson’s disease.
- Appointed Gene Mack as CFO and Jonas Hannestad, M.D., Ph.D. as CMO.

## SEC filing metadata
- accession: 0001558370-24-008129
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000155837024008129/0001558370-24-008129-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000155837024008129/ganx-20240514x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-008129
- JSON: https://secwatch.observer/filing/0001558370-24-008129.json
- Plain text: https://secwatch.observer/filing/0001558370-24-008129.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.